Technology area: Biotechnology & Pharmaceuticals
15 pending office actions • 10 art units • 12 examiners • 0 of 15 (0%) have an AI response strategy ready • 11 patents granted in the last 365 days
MannKind Corporation has 15 pending office actions in Biotechnology & Pharmaceuticals. The matters involve 12 examiners across 10 art units, reflecting a substantial and distributed prosecution docket. The lower examiner and art-unit figures relative to pending matters indicate repeated assignments within the portfolio, creating opportunities for coordinated review of recurring examination issues.
OLSEN, KAELEIGH ELIZABETH is the busiest examiner, with 2 pending matters. That examiner is the clearest concentration point in the profile, although the broader docket remains spread across multiple examination teams. Counsel should coordinate related biotechnology or pharmaceutical positions where appropriate, while preserving matter-specific responses for the remaining assignments.
Based on the USPTO statutory response window for each pending office action. 3 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 3 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 2 (13%) |
| §103 only | 4 (27%) |
| Double-patenting only | 2 (13%) |
| Double-patenting + other | 4 (27%) |
| Multi-statute (no §101) | 3 (20%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| OLSEN, KAELEIGH ELIZABETH | 2 | 47.1% | +64.3% |
| CHANDRA, GYAN | 2 | 71.3% | +27.5% |
| HAGHIGHATIAN, MINA | 2 | 46.0% | +39.4% |
| TCHERKASSKAYA, OLGA V | 1 | 55.5% | +46.4% |
| ROBINSON, KYLE G | 1 | 11.7% | +16.6% |
| HIBBERT, CATHERINE S | 1 | 58.8% | +48.6% |
| MERCIER, MELISSA S | 1 | 72.1% | +5.8% |
| HOLLAND, PAUL J | 1 | 57.3% | +64.7% |
| PIHONAK, SARAH | 1 | 61.4% | +42.4% |
| ARNOLD, ERNST V | 1 | 48.2% | +12.8% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 5 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18861479 | METHOD AND COMPOSITION FOR TREATING LUNG DISEASES | TCHERKASSKAYA, OLGA V | — |
| 18847985 | OPTIMIZATION OF DOSING AND PRESCRIBING OF MEDICATION | ROBINSON, KYLE G | — |
| 18796217 | METHOD AND COMPOSITION FOR TREATING OBESITY | OLSEN, KAELEIGH ELIZABETH | — |
| 17996706 | CLOFAZIMINE COMPOSITION AND METHOD FOR THE TREATMENT OR PROPHYLAXIS OF VIRAL INFECTIONS | OLSEN, KAELEIGH ELIZABETH | — |
| 17755425 | Compositions of Clofazimine, Combinations Comprising Them, Processes for Their Preparation, Uses and Methods of Treatment Comprising Them | ARNOLD, ERNST V | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17983915 | DRY POWDER INHALER | HAGHIGHATIAN, MINA | 1d overdue |
| 18265660 | Method and Composition for Treating Pulmonary Fibrosis | PIHONAK, SARAH | 61d |
| 18861479 | METHOD AND COMPOSITION FOR TREATING LUNG DISEASES | TCHERKASSKAYA, OLGA V | — |
| 18847985 | OPTIMIZATION OF DOSING AND PRESCRIBING OF MEDICATION | ROBINSON, KYLE G | — |
| 18796217 | METHOD AND COMPOSITION FOR TREATING OBESITY | OLSEN, KAELEIGH ELIZABETH | — |
| 18728814 | PHARMACEUTICAL COMPOSITIONS AND METHODS | HIBBERT, CATHERINE S | — |
| 18593204 | METHOD OF TREATING DIABETES TYPE 2 BY ADMINISTERING ULTRARAPID ACTING INSULIN | CHANDRA, GYAN | — |
| 18440382 | USE OF ULTRARAPID ACTING INSULIN | CHANDRA, GYAN | — |
| Art Unit | Apps |
|---|---|
| 1615 | 3 |
| 1619 | 2 |
| 1674 | 2 |
| 1616 | 2 |
| 3685 | 1 |
| 1658 | 1 |
| 1656 | 1 |
| 1627 | 1 |
| 1613 | 1 |
| 1612 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18861479 | METHOD AND COMPOSITION FOR TREATING LUNG DISEASES | TCHERKASSKAYA, OLGA V | 1615 | §101§103§112 | Non-Final OA | — | Pending | Oct 29, 2024 |
| 18847985 | OPTIMIZATION OF DOSING AND PRESCRIBING OF MEDICATION | ROBINSON, KYLE G | 3685 | §101§103§112 | Final Rejection | — | Pending | Sep 17, 2024 |
| 18796217 | METHOD AND COMPOSITION FOR TREATING OBESITY | OLSEN, KAELEIGH ELIZABETH | 1619 | §103§112Other | Non-Final OA | — | Pending | Aug 06, 2024 |
| 18728814 | PHARMACEUTICAL COMPOSITIONS AND METHODS | HIBBERT, CATHERINE S | 1658 | §102§112DP | Non-Final OA | — | Pending | Jul 12, 2024 |
| 18714456 | FORMULATION AND METHOD FOR TOPICAL TREATMENT OF MYCOBACTERIUM ULCERANS IN BURULI ULCERS | MERCIER, MELISSA S | 1615 | §103 | Non-Final OA | — | Pending | May 29, 2024 |
| 18593204 | METHOD OF TREATING DIABETES TYPE 2 BY ADMINISTERING ULTRARAPID ACTING INSULIN | CHANDRA, GYAN | 1674 | DP | Non-Final OA | — | Pending | Mar 01, 2024 |
| 18440382 | USE OF ULTRARAPID ACTING INSULIN | CHANDRA, GYAN | 1674 | §102§103DP | Non-Final OA | — | Pending | Feb 13, 2024 |
| 18434301 | DELIVERY OF ACTIVE AGENTS | HOLLAND, PAUL J | 1656 | §103 | Non-Final OA | — | Pending | Feb 06, 2024 |
| 18265660 | Method and Composition for Treating Pulmonary Fibrosis | PIHONAK, SARAH | 1627 | DP | Final Rejection | 61d | Pending | Jun 06, 2023 |
| 17983915 | DRY POWDER INHALER | HAGHIGHATIAN, MINA | 1616 | §103DP | Non-Final OA | 1d overdue | Pending | Nov 09, 2022 |
| 17996706 | CLOFAZIMINE COMPOSITION AND METHOD FOR THE TREATMENT OR PROPHYLAXIS OF VIRAL INFECTIONS | OLSEN, KAELEIGH ELIZABETH | 1619 | §103§112 | Non-Final OA | — | Pending | Oct 20, 2022 |
| 17755425 | Compositions of Clofazimine, Combinations Comprising Them, Processes for Their Preparation, Uses and Methods of Treatment Comprising Them | ARNOLD, ERNST V | 1613 | §103§112 | Final Rejection | — | Pending | Apr 28, 2022 |
| 17392361 | REACTOR FOR PRODUCING PHARMACEUTICAL PARTICLES IN A PRECIPITATION PROCESS | HELM, CARALYNNE E | 1615 | §103 | Final Rejection | — | Pending | Aug 03, 2021 |
| 17309624 | Compositions of Bedaquiline, Combinations Comprising Them, Processes for Their Preparation, Uses and Methods of Treatment Comprising Them | TIEN, LUCY MINYU | 1612 | §103 | Non-Final OA | 9d overdue | Pending | Jun 10, 2021 |
| 17158997 | DRY POWDER INHALER | HAGHIGHATIAN, MINA | 1616 | §103DP | Final Rejection | — | Pending | Jan 26, 2021 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialMannKind Corporation has 15 pending office actions as of October 2026, spread across 10 art units and 12 examiners.
Kaeleigh Elizabeth Olsen has the most, with 2 of MannKind Corporation's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
